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Lipoprotein lipase (LPL) is responsible for the intravascular pro-
cessing of triglyceride-rich lipoproteins. The LPL within capillaries
is bound to GPIHBP1, an endothelial cell protein with a three-
fingered LU domain and an N-terminal intrinsically disordered
acidic domain. Loss-of-function mutations in LPL or GPIHBP1 cause
severe hypertriglyceridemia (chylomicronemia), but structures for
LPL and GPIHBP1 have remained elusive. Inspired by our recent
discovery that GPIHBP1’s acidic domain preserves LPL structure
and activity, we crystallized an LPL–GPIHBP1 complex and solved
its structure. GPIHBP1’s LU domain binds to LPL’s C-terminal do-
main, largely by hydrophobic interactions. Analysis of electrostatic
surfaces revealed that LPL contains a large basic patch spanning its
N- and C-terminal domains. GPIHBP1’s acidic domain was not de-
fined in the electron density map but was positioned to interact
with LPL’s large basic patch, providing a likely explanation for how
GPIHBP1 stabilizes LPL. The LPL–GPIHBP1 structure provides in-
sights into mutations causing chylomicronemia.
triglycerides | lipase | lipoproteins | X-ray crystallography | GPIHBP1
Lipoprotein lipase (LPL), the enzyme that mediates the lipo-lytic processing of triglyceride-rich lipoproteins (TRLs)
within capillaries, was identified more than 60 y ago (1, 2) and
has been studied intensively by biochemists and physiologists
worldwide. LPL is the central molecule in plasma lipid metab-
olism, hydrolyzing triglycerides within TRLs and releasing lipid
nutrients for vital tissues (e.g., heart, skeletal muscle, and adi-
pose tissue) (3). Genetic variation that alters the efficiency of
LPL-mediated TRL processing influences both plasma triglyceride
levels and the risk for coronary heart disease (4, 5). Interestingly,
LPL is synthesized and secreted by parenchymal cells, primarily
myocytes and adipocytes, but virtually all of the LPL in tissues is
found on the surface of capillaries, where it is bound to a
glycolipid-anchored protein, glycosylphosphatidylinositol-anchored
high density lipoprotein-binding protein 1 (GPIHBP1) (6, 7).
GPIHBP1, a member of the LU (Ly6/uPAR) protein family, is
expressed exclusively in capillary endothelial cells (6). Based on
protein homology considerations (8, 9), GPIHBP1’s LU domain
(75 residues in length) is predicted to adopt a three-fingered fold,
stabilized by five disulfide bonds. GPIHBP1 is unique within the LU
protein family in having a highly acidic and intrinsically disordered N-
terminal domain containing a sulfated tyrosine and numerous gluta-
mates and aspartates (21 of 26 consecutive residues in human
GPIHBP1 are aspartate or glutamate) (6, 10, 11). GPIHBP1 binds to
the C-terminal domain of LPL (12), and both the LU domain and the
acidic domain of GPIHBP1 contribute to the binding affinity (11).
From the standpoint of mammalian plasma triglyceride me-
tabolism, GPIHBP1 can be viewed as an indispensable partner
for LPL. First, GPIHBP1 is solely responsible for capturing LPL
within the interstitial spaces and shuttling it across endothelial
cells to its site of action in the capillary lumen (7). In the absence
of GPIHBP1, LPL remains stranded in the interstitial spaces.
Second, GPIHBP1-bound LPL is required for the margination of
TRLs along capillaries, allowing the lipolytic processing of TRLs
to proceed (13). In the absence of GPIHBP1, TRLs do not stop
along capillaries and simply “flow on by” in the bloodstream.
Third, the binding of GPIHBP1 stabilizes the structure of LPL
and thereby preserves its enzymatic activity. In the absence of
GPIHBP1, LPL’s hydrolase domain is highly susceptible to
spontaneous unfolding (as judged by hydrogen–deuterium ex-
change/mass spectrometry studies), resulting in a rapid decline in
catalytic activity (11). When LPL is complexed with GPIHBP1, the
unfolding of LPL and the concomitant loss of activity is markedly
inhibited. The ability of GPIHBP1 to prevent the unfolding of
LPL and preserve catalytic activity depends on GPIHBP1’s dis-
ordered acidic domain (10, 11). When the acidic domain is
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deleted, GPIHBP1 still binds to LPL, but the protective effects of
GPIHBP1 on LPL structure and activity are minimal or absent (10,
11). GPIHBP1 also inhibits the unfolding of LPL that is catalyzed
by physiologic inhibitors of LPL (ANGPTL4, ANGPTL3) (14).
The central importance of both LPL and GPIHBP1 in plasma
triglyceride metabolism is illustrated by the fact that missense
mutations that interfere with LPL–GPIHBP1 interactions pro-
foundly impair intravascular triglyceride processing, resulting in
severe hypertriglyceridemia (chylomicronemia) (15, 16). For ex-
ample, a p.C445Y mutation in LPL, first identified in the setting of
chylomicronemia, has little effect on LPL catalytic activity but
abolishes LPL’s ability to bind to GPIHBP1 (17). A variety of
amino acid substitutions in GPIHBP1’s LU domain have been
uncovered in patients with chylomicronemia, and all of those
abolish GPIHBP1’s ability to bind LPL (15). The p.C445Y muta-
tion in LPL and most disease-causing mutations in GPIHBP1 in-
terfere with proper disulfide bond formation and protein folding
(17, 18), making it difficult to draw conclusions about which amino
acids participate in the LPL–GPIHBP1 binding interface.
Although LPL has been studied intensively for >60 y, its
structure has never been determined, very likely because of the
susceptibility of LPL’s hydrolase domain to unfolding. In the
absence of a structure, the field has depended on inferences from
a homology model (19) predicted from the structure of pancre-
atic lipase (PL), a distantly related member of the same lipase
family (20). The structure of PL, solved alone or in a complex
with colipase (a cofactor that facilitates lipid binding) (21, 22),
suggested that LPL would have two principal domains—a con-
ventional α/β-hydrolase domain with a catalytic triad and a
C-terminal β-barrel domain that interacts with lipids (19).
Inspired by the biological importance of GPIHBP1 and the
discovery that GPIHBP1 stabilizes LPL structure and activity,
we sought to determine the structure of an LPL–GPIHBP1
complex, with the principal goals of clarifying interactions be-
tween the two proteins, understanding the molecular basis for
mutations causing human disease, and gleaning insights into how
GPIHBP1 preserves LPL structure and activity.
Results
Formation of Human LPL–GPIHBP1 Complexes. To assess the feasi-
bility of producing human LPL–GPIHBP1 complexes, we mixed
a high concentration of human LPL (produced in CHO cells)
with increasing amounts of soluble human GPIHBP1 (produced
in Drosophila S2 cells) and then subjected the mixture to native
polyacrylamide gel electrophoresis at pH 8.4 (Fig. 1). Because
LPL is a very basic protein, only small amounts of LPL entered
the gel. However, full-length soluble GPIHBP1 (GPIHBP121–151)
is a highly acidic protein, allowing LPL–GPIHBP1 complexes to
enter the gel and migrate as a distinct band (Fig. 1A). Our LPL/
GPIHBP1 titration studies revealed that human LPL binds to
human GPIHBP1 with 1:1 stoichiometry, consistent with findings
reported for bovine LPL (10). Interestingly, a synthetic peptide
corresponding to the disordered acidic domain of GPIHBP1
(GPIHBP121–53) also formed a complex with LPL and entered the
gel. That complex also exhibited 1:1 stoichiometry (Fig. 1B).
A Crystal Structure for the LPL–GPIHBP1 Complex. The discovery that
human LPL forms a stable 1:1 complex with GPIHBP1 prompted us
to purify milligram amounts of the complex for protein crystalliza-
tion. LPL (15 mg) was mixed with a twofold molar excess of
GPIHBP1 and subjected to size-exclusion chromatography. Frac-
tions corresponding to the LPL–GPIHBP1 complex were pooled
and concentrated to 15 mg/mL. Crystals were obtained in more than
40 different conditions; however, only those grown in 200 mM
magnesium acetate and 20% polyethylene glycol 3350 diffracted at a
sufficiently high resolution for data collection and analysis. Crystals
were harvested after 5 d, and diffraction data were collected at the
European Synchrotron Radiation Facility (Grenoble, France).
The structure of the LPL–GPIHBP1 complex (2.8-Å resolu-
tion) was determined by molecular replacement methods using
the coordinates for the N- and C-terminal domains of horse
Fig. 1. Human GPIHBP1 binds to LPL with 1:1 stoichiometry, as judged by native polyacrylamide gel electrophoresis. In the absence of GPIHBP1, little LPL
enters native polyacrylamide gels and does not migrate as a distinct band, simply because LPL is a very basic protein. GPIHBP1 is highly acidic; thus, an LPL–
GPIHBP1 complex readily enters native gels and migrates as a distinct band. (A) Binding stoichiometry of LPL and GPIHBP1, determined by titrating 1.5 μM
human LPL (lane 1) with increasing amounts of full-length human GPIHBP1 [0.3–3.0 μM full-length GPIHBP1 (GPIHBP121–151)] (lanes 2–11). The relative
amounts of LPL–GPIHBP1 complexes (determined by scanning Coomassie blue-stained bands) are superimposed on the gels as black diamonds. These studies
reveal a 1:1 binding stoichiometry. (B) A similar titration of 7.6 μM LPL (lane 1) with increasing amounts of a synthetic peptide corresponding to the N-
terminal acidic domain of GPIHBP1 (GPIHBP121–53; 1–10 μM) (lanes 2–11). These experiments reveal 1:1 binding stoichiometry.
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pancreatic lipase (PDB ID code 1HPL) and our homology model
for GPIHBP1 (11). The structure was refined by manual curation
(Table 1). The quality of the electron density map for defined
regions within the N-terminal domain of LPL, the C-terminal
domain of LPL, and GPIHBP1 is illustrated in SI Appendix, Fig.
S1. The percentage of outliers in the Ramachandran plot (2.3%)
was similar to that reported for other lipases [3.3% and 2.6% for
human and bovine bile salt-stimulated lipase, respectively (23,
24); 2.3% for the pancreatic lipase–colipase complex (21); 4% in
the triacylglycerol lipase–colipase complex (25); and 2.3% in
pancreatic lipase–procolipase complex (26)]. Human LPL resi-
dues falling into disallowed regions of the Ramachandran plot
were generally confined to regions where the electron density
was not well defined or in regions of strained geometry (Table 1).
Two LPL–GPIHBP1 complexes were modeled in a head-to-tail
orientation in the crystallographic asymmetric unit (Fig. 2). LPL
consists of an N-terminal α/β-hydrolase domain containing 6
α-helices and 10 β-strands harboring the catalytic triad (S159, D183,
and H268) and a C-terminal flattened β-barrel domain containing
12 β-strands, connected by a hinge region. Electron densities were
missing for four short segments of LPL: (i) the first five amino acids
of the mature protein, residues 28–32; (ii) residues 249–258 in
LPL’s lid region (which controls entry of lipid substrates into
the active site cleft); (iii) residues 414–420 within a hydrophobic
Trp-rich motif reported to mediate TRL binding (13, 27); and (iv)
the last six amino acids of the protein (residues 470–475). While
10 of the residues in LPL’s lid region (a loop extending from the
C243–C266 disulfide bond) were not clearly defined in the struc-
ture, the trajectory of the amino acids adjacent to the disulfide bond
revealed that the lid was in an open conformation.
The LPL crystal structure revealed two N-linked glycans (N70,
N386), five disulfide bonds (C54–C67, C243–C266, C291–C302,
C305–C310, C445–C465), and a single calcium atom coordinated
by A194, R197, S199, D201, and D202. The active site cleft is
lined by the hydrophobic side chains of W82, V84, W113, Y121,
Y158, L160, A185, P187, F212, I221, F239, V260, V264, and
K265, which would form van der Waals interactions with (and
stabilize) the hydrophobic tails of lipid substrates in the active
site. Key structural features of LPL and GPIHBP1 are depicted
in the primary sequences shown in SI Appendix, Fig. S2.
The two LPL molecules in the crystal structure interact re-
ciprocally at a single site—between a C-terminal loop containing
the hydrophobic Trp motif in one LPL molecule and the catalytic
pocket in the N-terminal domain of the partner LPL molecule.
Electron densities were observed above the catalytic pocket in
both LPL–GPIHBP1 complexes (possibly corresponding to the
Trp motif), but the densities differed in the two LPL molecules
and could not be modeled satisfactorily, suggesting that in the
absence of lipids the Trp motif can adopt several conformations.
To identify potential conformations for the Trp motif (residues
414–421), we performed in silico modeling with the BioLuminate
and Prime modeling suite (Schrödinger). Five models were
generated by de novo loop creation for each of the two LPL
molecules in the crystal structure, followed by prime energy
minimization to choose the final model for each chain (28). The
overall orientation of the Trp motifs in each model was similar
with hydrophobic amino acids of the loop making contacts with
hydrophobic amino acids lining the active site pocket and thereby
burying a surface area of ∼600 Å2. In both models, W421 makes
similar contacts, but the orientations of Y414, F415, W417, and
W420 differ. In the model for chain A, F415 makes contacts with
F212, R214, G217, S220, and I221. W417 makes contacts with
F212, R219, I221, and I264. W420 interacts with W82, H120,
Y121, and P122. W421 docks and makes hydrophobic interactions
with the side chains of W82, Y121, P187, and I221 (SI Appendix,
Fig. S3A). In the second LPL molecule, Y414 interacts with F212,
F239, V263, and V264; F415 and S416 interact with L263 and
V264, respectively; W420 interacts with G215, R219, and I221; and
W421 contacts W82, Y121, P187, I221, and V264 (SI Appendix, Fig.
S3B). In each case, the docking of the Trp motif into the catalytic
pocket would explain the open lid conformation in the crystal
structure. The reciprocal interaction between the two LPLmolecules
was not a consequence of protein crystallization because the same
arrangement of molecules was observed in solution by small-angle
X-ray scattering (SAXS) analyses (Fig. 3 and SI Appendix, Table S1).
In the absence of lipids, we suspect that the hydrophobic Trp motif
of one LPL molecule is shielded by a hydrophobic docking site (e.g.,
the catalytic pocket) in the second LPL molecule.
The absence of electron densities for GPIHBP1 residues 21–
61 (which includes the entire acidic domain) was expected, given
that this region is intrinsically disordered and only binds LPL
transiently (10). Consistent with the presence of a classic LU fold
(8, 9), GPIHBP1 has three fingers stabilized by five disulfide
bonds (finger 1 containing βA–βB, amino acids 62–85; finger
2 containing βC–βD, amino acids 86–111; finger 3 containing
βE–βF, amino acids 112–130) (Figs. 2 and 4).
GPIHBP1–LPL Interactions. The LPL–GPIHBP1 binding interface
(∼940 Å2) involves the entire concave surface of GPIHBP1’s LU
domain, involves all three fingers, and is mediated largely by
hydrophobic interactions (Fig. 4). Of note, several van der Waals
interactions between nonpolar stems of charged amino acids
Table 1. Data collection and refinement statistics
PDB ID 6E7K
Wavelength, Å 1.000
Space group P21212
Unit cell, Å a = 101.9, b = 153.1, c = 95.7
Resolution range,* Å 95.80–2.80 (2.90–2.80)
Observed reflections 122,715
Unique reflections 37,662
Completeness, % 99.4 (99.7)
Redundancy 3.3 (3.2)
Rsym,
† % 7.4 (53.2)
Rpim,
‡ % 4.8 (35.7)
CC1/2 0.985 (0.728)
Overall <I/σ(I)> 13.5 (1.5)
Wilson B factor, Å2 79.7
Rcryst/Rfree,
§ % 19.7/23.5
No. of protein, water, glycan,
Ca2+ atoms
7,873, 16, 154, 2
Refined B factors for protein,
water, glycan, Ca2+, Å2
110.7, 97.7, 148.3, 115.0
Ramachandran outliers,¶ % 2.3
Bond lengths,# Å 0.010
Bond angles,# ° 1.433
*Values in parentheses are for the highest resolution shell.
†Rsym =
PjI− hIij=PI.
‡Rpim =
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
1=n− 1
p ðPjI− hIij=PIÞ, where I is the observed integrated intensity,
<I> is the average integrated intensity obtained from multiple measure-
ments, and the summation is over all observed reflections.
§Rcryst =
PjjFoj− kjFc jj=
P
Fo. Fo and Fc are the observed and calculated struc-
ture factors, respectively, and k is a scaling factor. The summation is over all
measurements. Rfree is calculated as Rcryst using 5% of the reflections chosen
randomly and omitted from the refinement calculations. Model stereochem-
istry was analyzed using MolProbity (56, 57).
¶Several residues falling into the disallowed area of the Ramachandran plot
were located in regions of strained geometry or in regions where the elec-
tron density is not well defined. For example, D33–I37 in the N terminus of
LPL had relatively poor electron density; S73 is positioned in a tight loop
connecting α1 and β2; S304 is flanked by disulfide bonds; M336 precedes a
proline; N359–Q360 connects β2′ and β3′; and L453–Q454 is in a tight loop
connecting β11′ and β12′.
#Bond lengths and angles are root-mean-square deviations from ideal
values.
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stabilize the complex (29). For example, LPL residues K464,
H466, and D467 make hydrophobic interactions with S107,
W109, and T111 of GPIHBP1. Finger 1 of GPIHBP1 interacts
with LPL residues 443–447 and 465–466; finger 2 interacts with
LPL residues 447–448 and 463–467; and finger 3 interacts with
amino acids 367, 374, 369, 403–406, 447, and 464 (Fig. 4 and
Dataset S1). All amino acid residues making hydrophobic con-
tacts between LPL and GPIHBP1 are listed in Dataset S1. In
addition, the side chain Ne of LPL R447 forms a hydrogen bond
with the main chain carbonyl of GPIHBP1 L103. Also, the side
chain of LPL E384 forms a hydrogen bond with GPIHBP1 E122,
either directly or indirectly through a water molecule (the elec-
tron density map does not permit a definite conclusion).
Before embarking on efforts to crystallize the LPL–GPIHBP1
complex, we suspected that the binding site for GPIHBP1 on
LPL might be similar to the binding site for colipase on PL. Our
suspicion was piqued by superficial similarities between GPIHBP1
and colipase: Both bind to the C-terminal domain of their lipase
partner, and both are small proteins with multiple loops and five
disulfide bonds. The LPL–GPIHBP1 structure revealed that
GPIHBP1 and colipase bind far apart (almost on opposite sides)
of the C-terminal domains of LPL and PL, respectively (Fig. 5).
Unlike the situation with GPIHBP1, where interactions with LPL
are largely hydrophobic and involve an extensive surface area, the
binding of colipase to PL depends primarily on electrostatic in-
teractions involving two short hairpin loops (21, 22, 30).
LPL Contains a Large Contiguous Basic Patch Spanning both N-Terminal
and C-Terminal Domains. LPL has long been recognized to have
multiple positively charged heparin-binding motifs (31–34). An
Fig. 3. Small-angle X-ray scattering (SAXS) analysis of the LPL–GPIHBP1 complex in solution. (A) SAXS data (gray circles) and the fit of the ab initio model
reconstructed using DAMMIF with P2 symmetry (green line). The Lower panel shows the error-weighted residual differences between the model fit and the
experimental data. (B) The real-space distance–distribution of the SAXS data and model. The Inset shows the superposition of the crystal structure of the LPL–
GPIHBP1 complex (PDB ID code 6E7K) with the filtered average ab initio model.
Fig. 2. Structure of the LPL–GPIHBP1 complex, as depicted by ribbon representations of the two LPL–GPIHBP1 complexes in the asymmetric crystallographic
unit. LPL (purple) has five disulfide bonds (C54–C67, C243–C266, C291–C302, C305–C310, and C445–C465); a single calcium ion (orange sphere) coordinated by
A194, R197, S199, D201, and D202; and two N-linked glycans (at N70 and N386). GPIHBP1 (green) has one N-linked glycan (at N78). LPL contains an N-terminal
α/β-hydrolase domain (N) containing 6 α-helices and 10 β-strands and a C-terminal flattened β-barrel domain (C) containing 12 β-strands, connected by a hinge
region. The numbering of the β-strands in GPIHBP1 follows the nomenclature proposed for LU domain proteins (55). IDR, intrinsically disordered region.
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electrostatic surface potential map, based on our crystallographic
structure, revealed that one surface of LPL has a large, flat, and
contiguous basic patch (∼2,400 Å2) involving both C- and N-
terminal domains and extending across LPL’s hinge region (Fig.
6). Two lysines (K472 and K473), located within the last five
amino acids of LPL, were disordered and could not be assigned in
the electron density map. Had those two lysines been visualized,
the size of the basic patch depicted in Fig. 6 may have been even
larger. The crystal structure shows that GPIHBP1’s acidic in-
trinsically disordered region (IDR) projects toward LPL’s basic
patch. The length of the acidic IDR (>60 Å) (10) would allow it to
make electrostatic interactions with LPL’s basic patch. We suspect
that these electrostatic interactions account for the ability of the
acidic domain to stabilize LPL structure and activity. Aside from
the role of GPIHBP1’s acidic domain in stabilizing LPL structure
(11), the functional relevance of LPL–GPIHBP1 electrostatic in-
teractions is evident from the ability of GPIHBP1’s acidic domain
to increase the association rate constant (ka) for LPL–GPIHBP1
complex formation by >250-fold (an effect highly dependent on
the ionic strength of the buffer) (10).
Fresh Insights into LPL Mutations Causing Chylomicronemia. Given
the very large interface between LPL’s C-terminal domain and
GPIHBP1’s LU domain, we suspected that we might find mis-
sense mutations that cause chylomicronemia by interfering with
LPL–GPIHBP1 interactions. We were intrigued by a report of a
chylomicronemia patient with a p.M404R mutation in LPL; this
mutation had been reported to abolish LPL secretion from cells
(35). Our LPL–GPIHBP1 crystal structure revealed that M404 in
LPL interacts with V121, E122, T124, and V126 in a hydro-
phobic pocket in finger 3 of GPIHBP1 (Fig. 7A and Dataset S1).
It is evident from the crystal structure that this hydrophobic
pocket on GPIHBP1 cannot accommodate the larger side chain
of arginine. We therefore reasoned that the p.M404R mutation
might actually cause disease by interfering with LPL–GPIHBP1
interactions. Indeed, the p.M404R mutation abolished binding of
LPL to GPIHBP1 (Fig. 8 A and B) but had little or no effect on
LPL secretion or activity (Fig. 8 B and C). As a control, we in-
cluded an LPLmutant harboring a p.C445Ymutation; that mutant
was shown previously to abolish LPL binding to GPIHBP1 without
affecting LPL secretion, heparin binding, or catalytic activity (17).
C445 in LPL is disulfide bonded to C465, and both cysteines par-
ticipate in the GPIHBP1 binding interface [C445 interacts with
GPIHBP1 residues K69 and S70 (Fig. 4 and Dataset S1); C465
interacts with GPIHBP1 residues K69, S70, and W109 (Fig. 4
and Dataset S1)]. As expected from earlier studies (17), LPL-
C445Y did not bind to GPIHBP1 (Fig. 8 A and B). As an addi-
tional control, we tested the ability of wild-type LPL to bind to a
mutant GPIHBP1 containing a p.W109S mutation. The p.
W109S mutation abolishes GPIHBP1’s capacity to bind LPL
and does so without interfering with proper disulfide bond
formation (36). The crystal structure revealed that W109 in
GPIHBP1 participates in the binding interface with LPL, inter-
acting with LPL residues K464, C465, H466, and D467 (Fig. 7B
and Dataset S1).
The structure of the LPL–GPIHBP1 complex also provided
insights into a p.D201V mutation in LPL, first observed in two
Lebanese kindred individuals with chylomicronemia (37). The
mechanism by which the p.D201V mutation causes disease was
never investigated. Our crystal structure revealed that the car-
boxylic acid side chain of D201 participates in the coordination
of LPL’s calcium ion via an ordered water molecule (Fig. 9A). A
valine at the same position cannot participate in calcium co-
ordination. We predicted that defective calcium coordination in
the p.D201V mutant would interfere with LPL folding and
prevent LPL secretion from cells. Indeed, the p.D201V mutation
eliminated LPL secretion from cells and markedly reduced LPL
activity levels in the medium (Figs. 8B and 9B). Substituting glutamic
acid for aspartic acid at position 201 had little effect on LPL secretion
or activity because the glutamic acid side chain can displace the in-
tervening water molecule and interact directly with the calcium ion.
We predicted that a glutamate substitution at the more sterically
constrained D202 (which interacts directly with the calcium ion)
would not be tolerated. Indeed, LPL-D202E was not secreted from
cells and LPL activity was virtually absent from the medium (Fig. 9B).
Discussion
After six decades of intensive investigation of LPL by biochem-
ists and physiologists worldwide, we succeeded in solving, by X-
ray crystallography, the atomic structure of LPL complexed to its
endothelial cell partner protein, GPIHBP1. The ability to crys-
tallize the LPL–GPIHBP1 complex depended on optimized
methods for expressing and purifying the two proteins (Materials
and Methods). Our suspension cultures of LPL/LMF1-transfected
cells allowed us to purify >20 mg of human LPL per L of cell
culture medium, and insect cell systems for expressing GPIHBP1
allowed us to purify up to 4 mg of GPIHBP1 per L of medium.
While protein production capabilities were an enormous boon for
the current project, the key to our success was the discovery, by
Mysling et al. (11), that LPL’s hydrolase domain is highly sus-
ceptible to spontaneous unfolding and that GPIHBP1 (and in
particular GPIHBP1’s disordered acidic domain) prevents the
unfolding. We suspect that the propensity of LPL’s hydrolase
domain to undergo unfolding largely explains our own failures,
despite considerable effort, to crystallize LPL alone. After generating
and purifying LPL–GPIHBP1 complexes, we quickly obtained
crystals that diffracted at a resolution of 2.8 Å.
Fig. 4. LPL–GPIHBP1 interactions. GPIHBP1 (green sticks, showing Cα posi-
tions and key side chains) forms a concave hydrophobic surface. That surface
interacts with the C-terminal domain of LPL (purple sticks, showing key LPL
side chains). A semitransparent surface of LPL is colored according to elec-
trostatic potential [red (acidic, −5 kBT), white (neutral, 0 kBT), and blue
(basic, 5 kBT)]. Electrostatic potentials were calculated with DelPhi (56). All
three fingers of GPIHBP1, but particularly fingers 2 and 3, interact with LPL,
largely by hydrophobic contacts.
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In seeking to solve the structure of a LPL–GPIHBP1 complex,
two of our key goals were to define the interactions of the two
proteins and to glean insights into mechanisms by which
GPIHBP1 stabilizes LPL structure and activity. For years, the
issue of how LPL and GPIHBP1 interact has remained elusive,
whereas the mechanisms for triglyceride hydrolysis by LPL could
be inferred from structural studies of other lipases (38–40). Our
crystal structure was extremely helpful in defining LPL–GPIHBP1
interactions. The structure showed that human LPL and human
GPIHBP1 bind with 1:1 stoichiometry, substantiating results from
our titration experiments with LPL and GPIHBP1 in solution.
Also, the LPL–GPIHBP1 crystal structure revealed that GPIHBP1’s
LU domain interacts, largely by hydrophobic contacts, with the
C-terminal domain of LPL. All three fingers of GPIHBP1 and
Fig. 6. Electrostatic surface of LPL showing the site
for GPIHBP1 binding. GPIHBP1’s LU domain forms a
concave hydrophobic surface that interacts with a
hydrophobic surface on the C-terminal domain (CTD)
of LPL (image on Right). LPL has a single large,
contiguous basic patch (∼2,400 Å2) spanning the
CTD, the hinge region, and the N-terminal catalytic
domain (Middle image). The C terminus of GPIHBP1,
where the GPI anchor would be attached, and the N
terminus of GPIHBP1, from which GPIHBP1’s acidic
intrinsically disordered region (IDR) projects, are
indicated by arrows (Middle and Right images).
GPIHBP1’s acidic IDR, >60 Å in length (10), is expec-
ted to project across and interact transiently with
LPL’s large basic patch (Middle image). The sequence
of GPIHBP1’s highly acidic IDR is shown in SI Ap-
pendix, Fig. S2. In the image on the Left, the catalytic
pocket is highlighted by a yellow dotted circle. The
Trp motif and lid sequences are depicted as dashed
green and cyan lines, respectively. Electrostatic po-
tentials were calculated as in Fig. 4.
Fig. 5. Distinct position for GPIHBP1 binding to LPL
compared with colipase binding to pancreatic lipase.
The structure of the LPL–GPIHBP1 complex (C-terminal
domain of LPL in purple; GPIHBP1 in green) is super-
imposed on that of the pancreatic lipase (PL)–colipase
complex (C-terminal domain of PL in khaki; colipase in
cyan), revealing that the binding sites for GPIHBP1
and colipase on the C-terminal domains of their
partner lipase (LPL and PL, respectively) are distinct.
Colipase binds by polar interactions to one face of the
flattened β-barrel via two hairpin loops (22), whereas
GPIHBP1 interacts with both faces through a large
hydrophobic interface. Both GPIHBP1 and colipase are
small multifingered proteins with five disulfide bonds;
however, the two proteins are evolutionarily distinct,
and the arrangement of the disulfide bonds in the
two proteins is different.
1728 | www.pnas.org/cgi/doi/10.1073/pnas.1817984116 Birrane et al.
multiple loops in LPL’s C-terminal domain participate in the
binding interface. It is predominantly the concave side of
the central β-sheet of GPIHBP1’s LU domain that shapes the
binding interface with LPL (Figs. 4 and 5). This binding ar-
chitecture resembles that for other members of the LU pro-
tein domain family. The concave surface of the extracellular
LU domain of activin receptors is responsible for ligand
binding (41, 42), and in the case of the urokinase receptor, the
concave surfaces of its three LU domains form a large hy-
drophobic cavity that binds urokinase with high affinity (43,
44). The crystallographic findings represent a significant im-
provement in understanding LPL–GPIHBP1 interactions and
aligns well with earlier hydrogen–deuterium exchange–MS analyses
(11). Our earlier efforts using alanine-scanning mutagenesis
studies provided limited insights, simply because the vast majority of
mutations that interfered with LPL–GPIHBP1 interactions did so
by preventing proper protein folding (18, 36, 45, 46).
The crystal structure revealed that one side of LPL (∼90° to the
side containing the catalytic pocket) contains a large, flat, and
contiguous basic patch—extending across LPL’s hinge domain and
involving large portions of LPL’s N- and C-terminal domains. For
years, the field has recognized that LPL contains multiple posi-
tively charged heparin-binding motifs, and the relative importance
of each of these motifs was a matter of considerable discussion
(31–34). Our crystal structure revealed that all of LPL’s linear
heparin-binding motifs merge into one contiguous basic patch in
the tertiary structure. Importantly, GPIHBP1’s N-terminal acidic
IDR, although not visualized in the electron density map, was
positioned to project in the direction of LPL’s basic patch. The
estimated length of GPIHBP1’s extended acidic IDR (>60 Å) (10)
would easily allow it to interact with the entirety of LPL’s basic
patch. We suspect that the interactions of GPIHBP1’s acidic do-
main with LPL’s basic patch, while transient in nature, serve to
stabilize LPL and inhibit the unfolding of its hydrolase domain.
We speculate that the acidic domain provides a continuous but
highly dynamic “chaperoning” function for LPL, stabilizing the
hinge domain and limiting the propensity of LPL’s N-terminal
domain to collapse and unfold.
GPIHBP1 and colipase are both small, cysteine-rich proteins,
and we had initially suspected that they might bind to similar
sites on their partner lipase (LPL and PL, respectively). This
suspicion was proven wrong; the binding sites for GPIHBP1 and
colipase for their partner lipase (LPL and PL, respectively) are
located far apart—almost on opposite sides of the lipase mole-
cules. In hindsight, the distinct binding sites are probably not too
surprising. While both GPIHBP1 and colipase have multiple
fingers and five disulfide bonds, they do not belong to the same
protein family and the disulfide bond arrangement is different.
Also, the two proteins serve different functions. Colipase func-
tions in lipid binding (30) and interacts directly with the lid
covering PL’s catalytic pocket (21, 22). GPIHBP1 is not involved
in lipid binding; its functions are to escort LPL across endothelial
cells and stabilize LPL structure (7, 10, 11, 14, 47). Finally, the
binding interactions of colipase and GPIHBP1 differ; colipase
binds to PL by electrostatic interactions (21, 22, 30), whereas
GPIHBP1 binding to LPL depends largely on hydrophobic contacts.
For many years, LPL has been assumed to form a head-to-tail
homodimer (19, 48–50), and recent studies have proposed that
homodimer formation is required for LPL secretion from cells
(51). In line with these assumptions, our crystallographic unit
contained two LPL–GPIHBP1 complexes arranged in a head-to-
tail orientation. The two LPL molecules interacted, in a re-
ciprocal fashion, between the Trp motif in the C-terminal
domain of one LPL and the catalytic pocket in the N-terminal
region of the partner LPL. SAXS studies on relatively dilute
samples in solution validated this quaternary structure. In our
crystal structure, LPL’s Trp motif, particularly residues 415–421,
were not resolved in the electron density map, but our in silico
model suggested that the Trp motif of one LPL interacts with the
catalytic pocket of the partner LPL. The head-to-tail topology of
LPL–LPL interactions that we observe in our crystal structure as
well as in solution by SAXS is remarkable because the presumed
lipid-binding Trp motif in one LPL occludes the catalytic pocket of
the partner LPL. To allow entry of triglyceride substrates into
LPL’s catalytic pocket, a certain degree of flexibility of the inter-
acting regions is likely required. The poorly defined electron den-
sities of the Trp-rich motif would be compatible with such
flexibility. One possible scenario is that the LPL–LPL interactions
that we observe in the crystal structure represent a transition state
that occurs physiologically in settings where TRLs are absent (e.g.,
LPL transiting across the interstitial spaces). At this time, our
presumption regarding protein flexibility in TRL binding and entry
of lipid substrates into the catalytic site remains to be clarified.
Fig. 7. Schematic diagrams depicting interactions between M404 in LPL and
GPIHBP1 and between W109 in GPIHBP1 and LPL. (A) Interactions of M404 in
LPL (purple) with a hydrophobic pocket formed by GPIHBP1 (green) (GPIHBP1
residues V121, E122, T124, and V126; all in finger 3 of GPIHBP1’s LU domain).
Replacing M404 with an arginine disrupts binding of LPL to GPIHBP1 (Fig. 8).
(B) Hydrophobic interactions between W109 in GPIHBP1 and LPL. GPIHBP1-
W109 is located in a hydrophobic pocket and interacts with multiple LPL res-
idues (Dataset S1). This figure depicts the C445–C465 disulfide bond in LPL but
does not show all of the hydrophobic interactions between those two cyste-
ines and GPIHBP1. LPL-C445 interacts with GPIHBP1 residues K69 and S70;
LPL-C465 interacts with multiple GPIHBP1 residues (Dataset S1). A p.C445Y
mutation in LPL abolishes binding of LPL to GPIHBP1 (17), likely by disrupting
the conformation of the loop established by the C445–465 disulfide bond.
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Fig. 8. Testing the impact of an LPL missense mutation (p.M404R) on GPIHBP1 binding. (A) CHO cells that had been transfected with S-protein–tagged
versions of wild-type (wt) human GPIHBP1 or GPIHBP1-W109S (or empty vector) were coplated with cells that had been transfected with V5-tagged versions
of human LPL-wt, LPL-M404R, or LPL-C445Y. The p.W109S mutation in GPIHBP1 and the p.C445Y mutation in LPL interfere with LPL–GPIHBP1 interactions (17,
35). The ability of LPL to bind to GPIHBP1 on the surface of cells was assessed by immunocytochemistry. Freshly secreted LPL-wt (green) was captured by
GPIHBP1 (red), resulting in colocalization of LPL and GPIHBP1 in the merged image. GPIHBP1-W109S has no capacity to bind LPL-wt; consequently, no
colocalization was observed on the merged image. LPL-M404R had little or no capacity to bind to GPIHBP1 (no colocalization on the merged image). (B) LPL
activity and mass assays revealed that LPL-M404R is catalytically active but binds poorly to GPIHBP1. Fresh medium from CHO cells that had been transfected
with FLAG-tagged human LPL-wt, LPL-M404R, or LPL-C445Y was added to wells of a 96-well ELISA plate that had been coated with a FLAG-specific antibody
(FLAG-Ab) or with human GPIHBP1. Relative amounts of LPL mass were assessed with an HRP-labeled monoclonal antibody against LPL (5D2) and plotted as
optical density (OD). LPL-M404R was efficiently captured by the FLAG antibody, but little LPL-M404R was captured by GPIHBP1. LPL-M404R binding to
GPIHBP1 was reduced by 79% and 85% in two independent experiments (compared with LPL-wt binding to GPIHBP1). Triglyceride hydrolase activity of LPL
captured on FLAG antibody-coated wells was assessed with [3H]triolein as the substrate. LPL-wt, LPL-M404R, and LPL-C445Y were catalytically active. (C)
Assessing LPL-M404R catalytic activity and secretion from cells. CHO cells were transfected with V5-tagged versions of LPL-wt, LPL-D201V, LPL-M404R, or LPL-
S159G (mutation of the critical serine in LPL’s catalytic triad). The LPL in cell lysates and media was assessed by Western blotting with a V5 antibody (green).
Actin (red) was used as a loading control. LPL activity in the medium was assessed with a [3H]triolein substrate. LPL-M404R was synthesized and secreted by
CHO cells, and there was robust LPL-M404R catalytic activity in the cell culture medium. The enzymatic activity of LPL-M404R was 103%, 110%, 115%, and
103% of the activity of LPL-wt in four independent experiments.
1730 | www.pnas.org/cgi/doi/10.1073/pnas.1817984116 Birrane et al.
Our LPL–GPIHBP1 structure provides fresh insights into
human mutations causing chylomicronemia. A p.M404R LPL
missense mutation, first identified in a Swedish patient with
chylomicronemia, had been reported to abolish LPL secretion
and activity (35). However, based on the location of M404 in the
LPL–GPIHBP1 binding interface, we suspected that it might ac-
tually cause chylomicronemia by interfering with LPL–GPIHBP1
interactions. Indeed, the p.M404R mutation abolished the ability
of LPL to bind to GPIHBP1 but had little or no effect on LPL
secretion or activity. The LPL–GPIHBP1 crystal structure was also
instrumental in defining the mechanism for chylomicronemia in
patients carrying a p.D201V LPL mutation. The carboxylic acid
side chain of D201 is critical for coordinating LPL’s calcium ion,
and we suspected that disrupting calcium binding would de-
stabilize LPL folding and prevent secretion from cells. Indeed,
there was no secretion of LPL-D201V from cells, nor was there
secretion of LPL with a mutation in another calcium-coordinating
residue (p.D202E). These studies defined a molecular mechanism
for human chylomicronemia, but the fact that a mutation in a
calcium-coordinating residue would elicit disease is not unprece-
dented. Others have documented that a mutation in a calcium-
coordinating residue in desmoglein 4 causes a hair abnormality
in rats (52), and missense mutations involving putative calcium-
coordinating residues in fibrillin-1 have been reported to cause
Marfan syndrome (53). As we look to the future, we have little
doubt that insights from the LPL–GPIHBP1 structure, combined
with biochemical and biophysical assays, will make it possible to
define mechanisms for other “chylomicronemia mutations”—
and even define mechanisms by which common LPL polymor-
phisms affect plasma triglyceride levels (54). Also, we suspect
that the LPL–GPIHBP1 structure will ultimately prove to be
helpful in designing highly stable versions of LPL for enzyme
replacement therapy.
Materials and Methods
Human LPL harboring an R324A mutation was expressed in CHO cells along
with lipase maturation factor 1, and LPL was purified from the medium on a
butyl-Sepharose column followed by heparin-Sepharose chromatography.
Human GPIHBP1 was expressed in Sf9 cells and purified to homogeneity by
several chromatography procedures. The LPL was mixed with GPIHBP1, and
the LPL:GPIHBP1 complex was purified by size-exclusion chromatography.
Crystals were obtained in 200 mM magnesium acetate and 17–22% poly-
ethylene glycol 3350. Diffraction data were collected at the ID30B beamline at
the European Synchrotron Radiation Facility (Grenoble, France). The structure
of the LPL:GPIHBP1 complex was solved by molecular replacement using co-
ordinates for the N- and C-terminal domains from horse pancreatic lipase (PDB
ID code 1HPL). SAXS data on the LPL:GPIHBP1 complex were collected on the
European Molecular Biology Laboratory (EMBL) P12 beamline of the storage
ring PETRA III [Deutsches Elektronen-Synchrotron (DESY), Hamburg, Germany]
and used to generate low-resolution shapes. To analyze the impact of LPL
mutations, CHO cells were transfected with both wild-type and mutant ver-
sions of an LPL expression vector (12, 16–18, 36). LPL and GPIHBP1 in cell lysates
and cell culture medium were analyzed by Western blotting and solid-phase
immunoassays. Triglyceride hydrolase activity was measured with a [3H]triolein
substrate, and esterase activity was measured with a 1,2-di-O-lauryl-rac-glycero-
3-glutaric acid 6′-methylresorufin ester (DGGR) substrate. A detailed descrip-
tion of materials and methods can be found in SI Appendix.
ACKNOWLEDGMENTS. We are grateful to the leadership of Shire US Drug
Discovery for their support; to Kevin Holmes, John Gill, and Anna Tchoudakova
for a human LPL-expressing cell line; Angela Norton, Bohong Zhang, and Leigh
Low for their early contributions to the production of recombinant LPL; and to
Shire’s Process Development Department for providing purified LPL used in
the crystallography and SAXS experiments. X-ray diffraction data were col-
lected at the ID30B beamline at the European Synchrotron Radiation Facility
(Grenoble, France), and SAXS data were collected at the EMBL P12 beamline of
the storage ring PETRA III (DESY, Hamburg, Germany). We acknowledge sup-
port from Fondation Leducq Transatlantic Network Grant 12CVD04 (to S.G.Y.,
A.P.B., L.G.F., and M.P.); National Institutes of Health Grants HL090553 (to
S.G.Y.), HL087228 (to S.G.Y.), HL125335 (to S.G.Y.), and HL139725 (to S.G.Y.);
Lundbeck Foundation Grant R230-2016-2930 (to K.K.K.); and NOVO Nordisk
Foundation Grants NNF17OC0026868 (to M.P.) and NNF18OC0033864 (to
M.P.). Research was partly funded by Shire US Drug Discovery.
Fig. 9. The calcium binding site in human LPL. (A) Stick representation of
LPL’s Ca2+ binding site, showing main-chain and side-chain hydrogen
bonding (dashed yellow lines). Difference electron density maps were con-
toured at 7σ (blue) and 2.8σ (cyan) for the calcium atom and water (w)
molecules, respectively. (B) Assessing the impact of mutations in calcium-
coordinating amino acids on LPL secretion from cells. CHO cells were trans-
fected with FLAG-tagged versions of wild-type (wt) human LPL and several
mutant LPLs (D201V, D201E, D202E, and S159G). LPL-S159G is an inactivating
mutation in LPL’s catalytic triad. A Western blot with a FLAG-specific anti-
body (green) was used to detect LPL in cell lysates and the cell culture me-
dium. Actin (red) was used as a loading control. (C) LPL activity in the
medium of LPL-transfected cells. LPL activity was assessed with a [3H]triolein
substrate (triglyceride hydrolase activity) and a DGGR substrate (esterase
activity). The catalytic activities of the different LPL proteins are plotted as a
percentage of those observed with LPL-wt (set at 100%). Based on the
structure of LPL, we predicted that replacing D201 with a glutamate would
not interfere with calcium coordination, whereas replacing D202 with a
glutamate would disrupt calcium binding. D202 is buried and the extra
methylene in a Glu mutation would not allow calcium coordination. D201 is
located on the surface, and a Glu in that position retains the ability to co-
ordinate calcium. LPL-D201V activity was 10.5%, 6.1%, 4.1%, and 12.9% of
LPL-wt in four independent experiments; LPL-D201E activity was 100% and
127% of LPL-wt in two independent experiments; LPL-D202E activity was
1.6% and 0.0% of control in two independent experiments.
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